Cookie Policy: This site uses cookies to improve your experience. You can find out more about our use of cookies in our Privacy Policy. By continuing to browse this site you agree to our use of cookies.
AdipoGen Life Sciences
NAI-112
100
CHF
CHF 100.00
In stock
AG-CN2-0309-M0011 mgCHF 100.00
AG-CN2-0309-M0055 mgCHF 400.00
| Product Details | |
|---|---|
| Synonyms | Lantibiotic NAI 112 |
| Product Type | Chemical |
| Properties | |
| Formula |
C109H147N25O31S2 |
| MW | 2367.6 |
| CAS | 1498289-64-7 |
| Source/Host Chemicals | Isolated from Actinoplanes sp. |
| Purity Chemicals | ≥80% (HPLC) |
| Appearance | Beige powder. |
| Solubility | Soluble in DMSO, aqueous acetonitrile or ethanol. |
| Identity | Determined by 1H-NMR and MS. |
| Declaration | Manufactured by Naicons Srl. |
| Other Product Data |
Purity Note: The purity is referred exclusively to the main congener(s), the sample also contains minor related congeners. See: A glycosylated, labionin-containing lanthipeptide with marked antinociceptive activity: M. Iorio, et al.; ACS Chem. Biol. 9, 398 (2014) |
| InChi Key | PFZIDZPCKNACSM-QOJXDRFFSA-N |
| Smiles | O=C(NC(CC1(C(NC(CC2=CNC3=C2C=CC=C3)C(NC(CO)C(NC(CC(N)=O)C(NC(C(O)=O)CSC1C)=O)=O)=O)=O)NC4=O)C(NC(CO)C(NC4CC5=CC=CC=C5)=O)=O)C6CCCN6C(C(CC7=CN(C8OC(C)C(O)C(O)C8O)C9=C7C=CC=C9)NC(CNC(C%10N(C(C(CSC%11)NC(C%12N(CCC%12)C(C(CO)NC(C(CO)NC(C(C(C)C)NC(C%11%13NC(C(CC(C)C)NC(/C(NC(C(C%13)NC(C(C(C)C)N)=O)=O)=C/C)=O)=O)=O)=O)=O)=O)=O)=O)CCC%10)=O)=O)=O |
| Shipping and Handling | |
| Shipping | AMBIENT |
| Short Term Storage | +4°C |
| Long Term Storage | -20°C |
| Handling Advice |
Keep cool and dry. Protect from light. Protect from light when in solution. |
| Use/Stability | Stable for at least 2 years after receipt when stored at -20°C. |
| Documents | |
| MSDS |
 Download PDF |
| Product Specification Sheet | |
| Datasheet |
Download PDF |
Description
-
Labionin-containing class III lanthipeptide.
-
Antinociceptive agent. Effective in animal models of nociceptic and inflammatory pain.
-
Does not act through opioid, cannabinoid or descending adrenergic mechanisms. Most likely acts through the vanilloid-sensitive pathway by a novel target. It can be developed for the treatment of neuropathic pain.
-
Weak antibacterial compound.
Product References
-
A glycosylated, labionin-containing lanthipeptide with marked antinociceptive activity: M. Iorio, et al.; ACS Chem. Biol. 9, 398 (2014)
-
Discovering new bioactive molecules from microbial sources: P. Monciardini, et al.; Microb. Biotechnol. 7, 209 (2014) (Review)
Related Products
